GATC Biotech sequenced four gram-positive and five gram-negative genomes from genomic DNA, to produce genome coverage from 15-fold to 30-fold, with a genome size of 3-5 Mb, depending on the genome. The genomes were sequenced for several customers, from within industry and academia, and these initial results will be used to drive the individual customer’s research and development programme by sequencing and comparing the optimised strains.
GATC Biotech is the only company in Europe that offers all three lead genome sequencing technologies, the ABI 3730, Illumina/Solexa 1G and Roche 454. GATC Biotech used the Illumina/Solexa 1G sequencing platform for the major part of the discovery of these nine new bacterial genomes and also used a combination of the other two technologies to produce raw data for the remaining genomes. Part of GATC Biotech’s contribution to these genome projects was de novo sequencing of the organisms, while part was re-sequencing projects.
Katie Odgaard | Source: alphagalileo
Further information:
www.gatc-biotech.com/en/discover_gatc/presse/meldungen/2007_04_nine_genomes.php
More articles from Life Sciences:
New cancer target for non-Hodgkin's lymphoma
24.11.2009 | New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
New hydrogen-storage method discovered
24.11.2009 | Carnegie Institution
Daycare may double TV time for young children
24.11.2009 | Studies and Analyses
Insomnia prevalent among cancer patients who receive chemotherapy
24.11.2009 | Studies and Analyses
24.11.2009 | Social Sciences
Multidisciplinary meeting on Urological Cancers aims to benefit cancer patients
20.11.2009 | Event News
'Golden Age' for clinical psychology in Northern Ireland
20.11.2009 | Event News
New Perspectives in Marine Anti-Fouling Research
11.11.2009 | Event News